Uses of rifamycins

A technology of rifamycin and erythromycin, which is applied in the treatment of osteomyelitis and foreign body infection in patients who need treatment, and can solve the problem of damage to the phagocytic bactericidal ability of granulocytes at the implantation site

Inactive Publication Date: 2009-02-11
ACTIVBIOTICS PHARMA
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In addition, subcutaneous implants have been shown to impair the phagocytic bactericidal capacity of implanted granulocytes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Uses of rifamycins
  • Uses of rifamycins
  • Uses of rifamycins

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0287] Example: Efficacy of 25-O-desacetyl-3'-hydroxy-5'-(4-methylpiperazinyl)benzoxazine rifamycin against Staphylococcus aureus in a foreign body infection model

[0288] We evaluated 25-O-desacetyl-3′-hydroxy-5′-(4-methylpiperazinyl)benzoxazine rifamycin (compound No. 86) alone and in combination with levofloxacin (LVX). Use, against Staphylococcus aureus in an established foreign body infection model (JID 1982; 146:486).

[0289] Methods: Four Teflon cages were implanted in the ventral side of guinea pigs. After two weeks, use 2 x 10 4 Cfu Staphylococcus aureus ATCC 29213 was inoculated into the cages. 24 hours after infection, the animals were treated by intraperitoneal injection every 12 hours for four consecutive days (see Table 4). Five days later, the tissue fluid in the cage was aspirated and cultured to detect floating Staphylococcus aureus. Then the cage was taken out, vortexed and incubated in broth medium at 37°C for 12h to detect adherent Staphylococcus aure...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides methods, compositions, and kits for treating a variety of bacterial infections, including prosthetic joint infections, infections caused by medical implants, infectious arthritis, and osteomyelitis. The methods, compositions, and kits employ rifamycins of any one of formulas (I)-(V).

Description

Background technique [0001] The invention relates to the field of antibacterial drugs. [0002] Joint therapy (joint replacement) is the primary means of reducing pain and improving mobility in patients with joint damage. Infection caused by prosthetic joints is an important complication with a high mortality rate and high treatment costs. In addition to the prolonged length of hospital stay, patients may experience complications from additional surgery and antimicrobial therapy, as well as the risk of redisability. [0003] The incidence of infection depends on the type of prosthesis. According to a study of hip and knee prostheses, the incidence of infection was 5.9 / 1000 prosthesis-years (prosthesis-years) in the first two years after implantation and 2.3 / 1000 in the following eight years Prosthesis - years. The incidence of prosthetic joint infections may have increased due to (i) better assays for microbial films involved in prosthetic joint infections, (ii) an increas...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/54A61K31/495A61K31/535A61K31/50A01N43/58A01N43/16A01N43/60A61K31/35
CPCA61K31/7034A61K31/50A61K38/14A61K31/54A61K31/65A61K31/496A61K31/35A61K31/43A61K45/06A61K31/535A61K31/495A61K31/545A61K31/57A61K31/7048Y02A50/30A61K2300/00
Inventor 克里斯托佩尔·K·墨菲戴维·M·罗特施泰因
Owner ACTIVBIOTICS PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap